Table 1:
Characteristics of patients at baseline in the Canadian Treatments for COVID-19 trial
| Characteristic | No. (%)* of patients receiving remdesivir n = 634 |
No. (%)* of patients receiving standard of care n = 647 |
|---|---|---|
| Age, yr, median (IQR) | 65 (53 to 77) | 66 (54 to 77) |
| Female sex | 260 (41.0) | 255 (39.4) |
| Clinical Frailty Score, median (IQR) | 3 (3 to 5) | 3 (2 to 5) |
| Time from symptom onset, to hospital admission, d, median (IQR) (n = 1210) | 6 (3 to 9) | 6 (4 to 9) |
| Time from hospital admission to symptom onset for nosocomial acquisition (n = 65), d, median (IQR) | 16 (7 to 40) | 8 (5 to 16.5) |
| Time from symptom onset to randomization, d, median (IQR) | 8 (5 to 11) | 8 (6 to 11) |
| Diabetes† | 155 (33.6) | 188 (38.4) |
| Chronic respiratory disease† | 67 (14.5) | 65 (13.3) |
| Asthma† | 49 (10.6) | 55 (11.2) |
| Smoker† | 23 (5.0) | 22 (4.5) |
| Chronic cardiovascular disease† | 120 (26.0) | 135 (27.6) |
| Chronic liver disease† | 8 (1.7) | 19 (3.9) |
| HIV positive† | 1 (0.2) | 1 (0.2) |
| Ethnic group‡ | ||
| White | 269 (42.4) | 255 (39.4) |
| South Asian | 90 (14.2) | 110 (17.0) |
| East Asian | 40 (6.3) | 42 (6.5) |
| Indigenous or First Nations | 40 (6.3) | 28 (4.3) |
| Black | 20 (3.2) | 25 (3.9) |
| Arab | 22 (3.5) | 24 (3.7) |
| Latin American | 23 (3.6) | 21 (3.2) |
| West Asian | 8 (1.3) | 12 (1.9) |
| Other | 9 (1.4) | 14 (2.2) |
| Not available | 119 (18.8) | 126 (19.5) |
| Employed as a health care worker | 29 (4.6) | 28 (4.3) |
| Corticosteroid use | 553 (87.2) | 564 (87.2) |
| Tocilizumab use | 14 (2.2) | 5 (0.8) |
| Baseline severity at randomization | ||
| Patient in ICU | 139 (21.9) | 135 (20.9) |
| Organ support on day 0 | ||
| No organ support | 71 (11.2) | 54 (8.4) |
| Low-flow oxygen | 334 (52.7) | 363 (56.2) |
| High-flow nasal oxygen | 149 (23.5) | 153 (23.7) |
| Noninvasive ventilation | 22 (3.5) | 23 (3.6) |
| Invasive mechanical ventilation | 58 (9.1) | 54 (8.3) |
Note: ICU = intensive care unit, IQR = interquartile range.
*
Unless otherwise specified.
†
All the unavailable, unknown and missing values were set to “No.” Data on these comorbidities are available for a subset of patients: n = 951 (n = 461 in remdesivir and n = 490 in control group).
‡
Percentages add to more than 100% as multiple ethnic groups might have been chosen.